Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
SUNPHARMA
Mr. Kirti Wardhaman Ganorkar · Mumbai, India · 47,000 employees
₹1,989.90
▲+0.67%Sun Pharma is hovering near its 52‑week high on modest price gains, buoyed by steady revenue growth and strong margins despite a high valuation.
Exchange
NSI
Currency
INR
Day range
₹1,960.40 – ₹1,992.70
52-week range
₹1,548.00 – ₹1,993.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis78% confidence
The stock appears slightly overvalued relative to peers given its P/E of ~42, but the strong growth and margin profile provide some upside cushion near the top of its 1‑year range.
0.2% below the 1-year high · trend up
Hedge-fund memo
Today
Up 0.67% on modest buying pressure, trading in the upper third of its 52‑week range.
This week
Price has consolidated above 1970 INR, reflecting support near the 52‑week high.
This month
The last month saw a gradual rally from the low‑1500s, driven by positive earnings outlook and analyst upgrades.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
8 headlines · 6 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
11.3 vs 11.81215
-4.34% surprise
15.4819 vs 12.72765
21.64% surprise
13 vs 11.96722
8.63% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| SUNPHARMA | 4.77T | 41.59 | 14.72% | 19.23% | 12.80% |
| CIPLA | 1.19T | 35.31 | — | 12.55% | 3.50% |
| LUPIN | 1.12T | 21.02 | 26.91% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Debt servicing pressure from high leverage
Mitigation: Monitor cash‑flow generation and any refinancing announcements.
Regulatory pricing cuts in major export markets
Mitigation: Diversify revenue mix toward domestic growth and higher‑margin specialties.
Business intelligence
Competitive moat
Scale of manufacturing, extensive global regulatory approvals, and a diversified product portfolio give Sun Pharma a cost and market‑access advantage.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Earnings release with EPS guidance
Regulatory approval of a new biosimilar product
Thesis builder
Bull case
Continued revenue expansion from generic and specialty launches, coupled with margin resilience, will support earnings multiple expansion.
Base case
Steady top‑line growth of ~12% YoY and ROE around 15% sustain the current valuation.
Bear case
If debt servicing costs rise or regulatory pricing squeezes margins, the high P/E could lead to a correction.
Time horizon
12‑18 months
Est. CAGR
10‑13% annual revenue CAGR over the next 3‑5 years
Entry (qual.)
Buy on dips near 1950‑1970 INR, especially on pullbacks in volume.
Exit (qual.)
Consider partial profit‑taking if price exceeds 1995 INR or if earnings guidance is revised downward.
Overall conviction 78%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how SUNPHARMA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain SUNPHARMA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Maintain a buy stance with a focus on entry near the current price and exit if the stock breaches the 1995‑2000 INR resistance zone.
TradingView·2d ago·regulatory resubmission for melanoma treatment
Stocktwits·3d ago·acquisition offer premium for OGN stock
TradingView·3d ago·revenue breakdown financial reporting
TradingView·5d ago·unrelated third-party share offloading
HDFC Sky·5d ago·shareholders approve major acquisition deal
Equitypandit·5d ago·weekly market outlook commentary
Upstox·5d ago·acquisition progress boosts investor focus
Yahoo Finance·6d ago·merger deal cleared by shareholders
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
11.9751 vs 12.58418
-4.84% surprise
| 24.22% |
| 31.90% |
| DRREDDY | 951.54B | 28.74 | 8.84% | 4.25% | -5.60% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,960.40
Resistance (day/52w high)
₹1,992.70
Volume
26,82,281
Trend
up
RSI (14)
64
MACD
bullish
MA cross
golden
50-day MA
₹1,869.25
200-day MA
₹1,772.76
vs 200-DMA
12.2%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.